Caitong International Asset Management Co. Ltd Has $589,000 Stock Position in Insmed, Inc. $INSM

Key Points

• Caitong International Asset Management Co. Ltd increased its stake in Insmed, Inc. by an astounding 97,516.7%, owning 5,857 shares valued at $589,000 as of the end of the second quarter.
• Insmed's quarterly earnings report revealed a loss of ($1.70) EPS, missing analysts' estimates and showing a year-over-year revenue growth of 18.9% with earnings of $107.42 million.
• A number of analysts have adjusted their target prices for Insmed, with Mizuho setting a new target at $165.00 and 19 research analysts rating the stock as a strong Buy.

Caitong International Asset Management Co. Ltd grew its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 97,516.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,857 shares of the biopharmaceutical company's stock after buying an additional 5,851 shares during the period. Caitong International Asset Management Co. Ltd's holdings in Insmed were worth $589,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Insmed by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock valued at $1,393,675,000 after buying an additional 49,149 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Insmed by 1.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock valued at $985,938,000 after buying an additional 219,131 shares during the period. Adage Capital Partners GP L.L.C. grew its holdings in shares of Insmed by 109.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock valued at $262,967,000 after buying an additional 1,799,382 shares during the period. Alliancebernstein L.P. boosted its stake in Insmed by 2.5% in the 1st quarter. Alliancebernstein L.P. now owns 2,423,513 shares of the biopharmaceutical company's stock worth $184,890,000 after purchasing an additional 59,952 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in Insmed by 3.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,602,655 shares of the biopharmaceutical company's stock worth $122,267,000 after purchasing an additional 56,048 shares during the period.

Insmed Trading Down 0.2%

Insmed stock opened at $160.12 on Friday. The firm has a 50-day moving average of $146.74 and a 200-day moving average of $107.38. Insmed, Inc. has a one year low of $60.40 and a one year high of $168.21. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The company has a market cap of $33.85 billion, a price-to-earnings ratio of -28.04 and a beta of 1.03.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same quarter in the prior year, the company earned ($1.94) earnings per share. The company's quarterly revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, equities analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on INSM shares. Mizuho upped their target price on shares of Insmed from $130.00 to $165.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 13th. JPMorgan Chase & Co. upped their target price on shares of Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 20th. Evercore ISI reaffirmed an "outperform" rating and issued a $180.00 target price on shares of Insmed in a research note on Wednesday, October 1st. UBS Group upped their target price on shares of Insmed from $140.00 to $194.00 and gave the stock a "buy" rating in a research note on Tuesday, October 14th. Finally, Guggenheim upped their target price on shares of Insmed from $125.00 to $172.00 and gave the stock a "buy" rating in a research note on Monday, September 8th. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Insmed currently has a consensus rating of "Moderate Buy" and a consensus target price of $152.88.

Insider Activity at Insmed

In other news, CEO William Lewis sold 6,865 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $128.40, for a total transaction of $881,466.00. Following the completion of the transaction, the chief executive officer directly owned 233,924 shares in the company, valued at $30,035,841.60. This represents a 2.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the transaction, the director owned 262,675 shares of the company's stock, valued at approximately $38,190,318.25. This represents a 3.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 152,657 shares of company stock worth $21,442,198. Corporate insiders own 3.00% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.